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Role of the Endocannabinoid System and
Medical Cannabis
Sabrina Jarvis, DNP, FNP, Sean Rassmussen, MS, and
Blaine Winters, DNP, ACNP
ABSTRACT

Our bodies produce complex substrates called endocannabinoids, which attach to the
endocannabinoid system (ECS) receptors and impact many physiologic processes.
Current research on the ECS and cannabis-based medications is accelerating in the
presence of continued conﬂict between federal and state laws. In this article we present
a summary of the latest information on the ECS, its receptors, and current research on
the cannabis-based medicines and their potential to treat various disease pathologies
and medical conditions. Our study includes the latest information on the continued
legal ramiﬁcations nurse practitioners face in treating patients with these medications.
Keywords: cannabis, endocannabinoid receptor, endocannabinoid system
Ó 2017 Elsevier Inc. All rights reserved.

INTRODUCTION

C

annabis has been highly valued and used by
many cultures throughout history for its
medicinal, euphoria, and relaxationenhancing properties. This usage dates back over
3,000 years with the report of anxiety relief with
bhang (cannabis consumed as food) in ancient India.1
In 2008, archeologists discovered cannabis in 2,500year-old tombs in eastern China. Genetic testing of
this ancient marijuana led researchers to believe it was
used for treating illness but also for its psychotropic
effects and spiritual purposes as well.2
It was not until much later that cannabis was
introduced into the United States. In 1619, King James
I ordered the Jamestown colonists to grow cannabis
plants for hemp export. The hemp ﬁbers were used to
manufacture ropes, paper, and fabric.3 In the 1850s,
medicinal preparations became available in American
pharmacies. Over the next 3 decades, recreational use
of cannabis ﬂourished in oriental-style hashish establishments.4 It was during this time that cannabis was
labeled as both a poison and narcotic.
In 1906, the Pure Drug and Food Act was passed
requiring that certain drugs, including cannabis, be
accurately labeled, and states began to restrict the sale
of cannabis.5 In 1937, the Marijuana Tax Act was
www.npjournal.org

passed, which made it illegal to possess or transfer
cannabis. In 1970, the Supreme Court determined
that the Marijuana Tax Act was unconstitutional. It
was during this time Congress passed the Controlled
Substance Act and listed cannabis as a Schedule
I drug.6
Cannabis possesses over 100 different cannabinoids
and has been found to modulate analgesia and antiinﬂammatory pathways and provide neuroprotection,
among other functions.7 In the 20th century, D9tetrahydrocannabinol (THC) was identiﬁed as a primary bioactive component of cannabis; this led to the
discovery and cloning of endogenous cannabinoid
receptors. It was also found that the body could produce naturally occurring substances, called endocannabinoids, which could mimic THC activity.
Endocannabinoids, their receptors, and the associated
mediating enzymes for synthesis and degradation
comprise the endocannabinoid system (ECS).8
In the US there are 3 categories of cannabinoid
medicines: single molecule drugs; cannabis-based
liquid extracts; and phytocannabinoid botanicals.7
Single molecule drugs are semisynthetic or synthetic
prescription drugs. The US Food and Drug
Administration (FDA) has approved 2 of these,
nabilone and dronabinol.7 The second category of
The Journal for Nurse Practitioners - JNP

525

cannabis-based liquid extracts includes the botanical
drug naximols, which is produced by the UK-based
GW Pharmaceuticals Co. This drug is currently undergoing FDA Phase III trials. They are looking at
whether there is a signiﬁcant difference between
naximols and placebo in reducing pain in patients
with advanced cancer.9
The last category of cannabinoid medicines is
phytocannabinoid botanicals, which includes the
Schedule I plant Cannabis sativa.7 These are dense
cannabis extracts usually available in capsule or pill
form. Other methods of delivery may include
sublingual sprays, transdermal patches, suppositories,
and topical ointments. An example of this category is
a Schedule III drug called Idrasil, which is used to
help alleviate pain and improve appetite.10
With the discovery of the ECS, scientists and
researchers have been petitioning to remove the
cannabis Schedule I drug restrictions so medical
research can more easily be done. Current research is
addressing the effects of exogenous cannabinoids in
treating symptoms of epilepsy, human immunodeﬁciency virus neuropathy, chemotherapy-induced
nausea, anorexia, multiple sclerosis spasticity, chronic
and neuropathic pain, glaucoma intraocular pressures,
and asthma-associated dyspnea.7 The FDA has
recently given approval for a study on the effect of
medical cannabis in treating military veterans with
posttraumatic stress disorder (PTSD).11
Currently, 25 states have passed laws permitting
limited use of medicinal cannabis for speciﬁc medical
conditions.12 Patients receive state authorizations to
procure and self-administer medicinal cannabis under
in-state medical supervision. Yet, many health-care
providers feel uncomfortable providing care to these
patients. Besides geographic considerations, there
continues to be a sociopolitical environment in
which state laws are in direct conﬂict with federal
laws, with potential serious legal consequences to
both provider and patient.12 Our aim in this study
was to provide current information about the ECS
and the research being done on medications that
directly impact the ECS to reduce or alleviate
disease-associated symptoms. Additional background
information is provided on current cannabis plant
medical research and the sociopolitical factors that
526
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continue to impact both the nurse practitioner and
patient in the decision to treat with cannabinoid
medications.
ECS

As a basic review, the ECS is comprised of endocannabinoids (eCBs), their receptors, and the associated mediating enzymes for synthesis and degradation.
It is a unique and complex system with the eCBs acting
as the only known retrograde synaptic neurotransmitters (see Figure).13 There are 5 known eCBs
produced by the body: anandamide (AEA); 2archidonoylglyceral (2-AG); 2-archidonoylglyceral
ether (noladin ether); O-archidonoyl ethanolamine
(virodhamine); and N-arachidonoyl dopamine.13
AEA and 2-AG are the 2 most commonly recognized
and studied eCBs ligands and are endogenous
arachidonate-based lipids.14 AEA was discovered in
1992 and helped to provide a basic understanding of

Figure. Retrograde endocannbinoid signaling (ﬁgure is
property of the authors).
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ECS-neuromodulating function. AEA’s effects occur
in both the central nervous system (CNS) and the
peripheral nervous system. There is less information on
noladin ether, virodhamine, and N-arachidonoyl
dopamine and their roles in the regulation of the
ECS.15 It is important to note eCBs are normally at
low levels when body homeostasis is balanced. They
only begin to be synthesized in large quantities when
stimulated. This activation can occur as a response to
painful stimuli, bacterial and/or viral infections, stress
response, or inﬂammation.16
Although cannabis plant cannabinoids directly
target cannabinoid type 1 receptors (CB1Rs) on the
presynaptic neuron, AEA and 2-AG are produced,
on demand, from lipid precursors found in the
postsynaptic neuron and released into the synaptic
space (see Figure). When depolarization of the
postsynaptic neuron occurs, the naturally inﬂuxed
calcium is thought to activate the enzyme
transacyclase. It is suggested this enzyme catalyzes the
ﬁrst step in the biosynthesis of eCBs by converting
phosphatidylethanolamine, a phospholipid, into Nacyl-phosphatidlethanolamine. The eCBs then travel
retrograde to the CB1 receptors on the presynaptic
neuron. The bound eCBs initiate a series of
biochemical reactions, which lead to a decrease in
inhibitory neurotransmitters (see Figure). This leads
to the direct result of increased activity of the
postsynaptic neuron. The AEA is then rapidly
inactivated by fatty acid amide hydrolase and the 2AG is broken down by monoacylglycerol lipase.17
The primary purpose of the ECS is to provide
homeostasis for many metabolic functions, such as
neurotransmitter, inﬂammation, and energy modulation. The ECS is located throughout the entire
body and is comprised of speciﬁc cannabinoid
receptors.
CANNABINOID RECEPTORS

The cannabinoid receptors are G-protein‒coupled
receptors that are activated by 3 major groups of ligands: endocannabinoids produced by the body;
cannabinoids produced from the cannabis plant; and
synthetic cannabinoids. The 2 principle subtypes of
cannabinoid receptors are CB1Rs and cannabinoid
type 2 receptors (CB2Rs).18
www.npjournal.org

CB1Rs reside heavily within the CNS and are
well known for their neurologic effects when activated. In addition to their presence within the brain,
CB1Rs are also found within digestive organs,
including the pancreas, liver, small intestines, and
large intestines. They have also been found within
muscle ﬁbers and adipocyte cells.16 Although CB1Rs
are scattered throughout the body, their role and
function within the CNS may hold the
most potential.
CB1Rs found within the hippocampus and limbic
system play a signiﬁcant role in the regulation of
emotions. When the hippocampus receptors are
activated, cannabis users often describe experiencing a
blissful euphoria.16 Clinical data suggests eCBs and
CB1Rs may modulate anxiety and depression.
Augmentation of eCB signaling has been found to
decrease depression and anxiety symptoms, whereas,
if the CB1Rs are blocked, increased symptoms will
occur.19 There are also CB1Rs located in the basal
ganglia and hypothalamus, which, when stimulated,
help regulate appetite and gastric motility. These
gastric effects led to the development of dronabinol, a
medication used to treat cancer-related anorexia and
nausea symptoms.16
CB2Rs are found in many areas in the body and,
unlike CB1Rs, have almost no psychoactive effects
when stimulated. Most are found along the spinal
column or in the bone marrow, whereas only a few
receptors are found within the brain.16 Although
both CB1Rs and CB2Rs have been found in
inﬂammation leukocyte mediators, CB2Rs are
predominant in leukocytes and appear to be the key
mediators of cannabinoid regulation of the immune
and inﬂammatory systems. When the CB2Rs are
blocked, there is inhibition of splenocyte production
and in-vivo cell death. When macrophage CB2Rs
are stimulated, they inhibit proliferation and the
release of pro-inﬂammatory factors, and decrease
phagocytosis.20 For example, in the presence of
ischemia, cardiomyocytes are subject to inﬂammation
and eventually cell death. In this state, CB2Rs are
agonized as part of the body’s natural response. When
researchers antagonized CB2Rs during hypoxia, both
inﬂammation and macrophage digestion were
minimized.21
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CB1Rs and CB2Rs play a role in modulating pain
pathways and helping to provide analgesia. In cancer
pain pathway research, cannabinoids act as analgesics
in patients with neuropathic pain and are antihyperalagesic. They have been shown to decrease
painful stimuli from sensory neurons in many animal
models. There are also indications cannabinoids may
potentiate the analgesic properties of morphine and
help prevent drug tolerance.22
In neuropathic pain, cannabinoids act on peripheral and central nerve CB1Rs and keratinocyte
CB2Rs. The peripheral nociceptor CB1Rs help
mediate and block painful stimuli to the sensory
neurons. CB2Rs located on the immune cells and
keratinocytes stimulate b-endorphin release and
decrease pain stimuli through m-opioid receptors.22
CANNABINOIDS

The cannabis plant contains over 400 naturally
occurring chemicals and approximately 100 cannabinoids.23 Cannabis is the root word and the scientiﬁc
plant genus from which all other names derive. There
are 3 subspecies of cannabis, including cannabis sativa,
cannabis indica, and cannabis ruderalis. Cannabis sativa
is the most widely cultivated plant in the US and
abroad for both commercial and pharmaceutical
use.24
The cannabis plant can be broken down into 4
major parts, the stems, seeds, ﬂowers or buds, and
leaves. Hemp is obtained from the stems and is used
to manufacture clothing, rope, paper, protein supplements, beauty products, and oils. There is no
abuse potential or medicinal beneﬁt from hemp or
hemp products.24
Female ﬂowers produce recreational and medicinal drugs, edible seeds, and essential oils.24 Dried
leaves and ﬂowers are smoked for their euphoric
and relaxation-enhancing properties.24 Cannabidiol
(CBD) and THC are the most commonly researched
cannabinoids. In 1940, CBD was extracted from
the cannabis plant and was found to have no
psychotropic effects.25 In 1964, THC, the primary
psychotropic cannabinoid, was discovered and ECS
research gained momentum.14
CBD targets CB2Rs with an agonizing effect.
Because CBD has very little impact on CB1Rs, the
psychoactive side effects are minimized. Colorado
528
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researchers manipulated cannabis plant genetics to
remove THC in an attempt to develop pediatric
epilepsy medical cannabis. The cannabis was found to
be ineffective. It was discovered the cannabinoids
work better together and produce a synergistic effect,
leading to improved clinical outcomes.26
This ﬁnding led to the development of the
specialized medical cannabis, Charlotte’s Web, which
is an example of medical cannabis high in CBD
and low in THC (< 0.3%).26 This unique formula
maintains better seizure control with minimal
psychoactive side effects. There is limited scientiﬁc
research on the mechanism of action for seizure
control, but it is theorized seizures affect the ECS and
produce an increased expression of CB1R protein in
the hippocampus. The CB1R agonistic activity
inhibits adenyl cyclase, which causes increased
potassium efﬂux and helps stabilize the potassium
channels. It also decreases calcium inﬂux in certain
calcium channels, which inhibits neuronal
hyperexcitability and seizure activity.27
Since 2014, GW Pharmaceuticals has been testing
another medical cannabis drug, Epidiolex, which has
a 99% CBD concentration and < 10% THC content.
It is being used to treat Dravet’s syndrome, a rare
form of epilepsy. In March 2016, the company
reported Phase III clinical trials of Epidiolex, which
showed some promising results. A nearly 40%
decrease in monthly convulsive seizures was observed
in study participants.28 The study was performed on
children between 6 and 10 years old who had
previously been on multiple anticonvulsants that had
failed to adequately control their seizures. The
company’s goal is to have the ﬁrst cannabis-based
drug approved by the FDA for seizure control in
children with epilepsy.28
MEDICAL CANNABIS RESEARCH

Besides research on the use of cannabinoids as anticonvulsant agents, many other ECS research studies
are being done. Animal model research suggests the
ECS may have an important role in the creation,
maintenance, and expenditure of energy.16 Another
study linked CB1Rs to the health and maintenance
of kidneys.29 The study revealed that kidney ﬁbrosis,
which often occurs in kidney disease and diabetes,
was worse in the presence of CB1R activation in
Volume 13, Issue 8, September 2017

kidney tissues. In mice, when CB1Rs were blocked,
there was a signiﬁcant decrease in kidney ﬁbrosis and
renal scarring.29 Some researchers believe medical
conditions, such as weight loss and diabetes, may
someday be controlled through CB1R
manipulation.16
According to a recent clinical review, compelling
evidence suggests medical cannabis may show
promise in the areas of chronic pain and spasticity
associated with multiple sclerosis. Both of these
conditions would call for THC as the primary
effector.23
Recent research has examined the role of CB1Rs
and cannabinoids in the treatment of PTSD in the
veteran population. There are known elevated
numbers of brain CB1Rs associated with PTSD.30
Currently, a $2,156,000 grant research project,
Marijuana for Symptoms of PTSD in US Veterans, is
being carried out.31
Other research is examining the effects of THC
on the treatment of memory loss and Alzheimer’s
disease. Animal model research has demonstrated
THC competitively inhibits the enzyme acetylcholinesterase and decreases amyloid b-peptide aggregation, a key marker of Alzheimer’s disease.32
Cannabinoids and their receptors are also being
studied for their roles in cancer tumor growth. Animal tumor models suggest eCBs may inhibit neoangiogenesis and tumor cell migration. These actions
may be receptor-independent based on the type of
tumor or tissue cell and the cannabinoid or eCB
expressed.33
For these and further studies to take place cannabis
needs to be legally grown, harvested, and supplied to
research institutions here in the US. Over the years,
researchers have struggled to gain access to medical
cannabis to complete their studies. Medical cannabis
has been used for research and clinical trials in animals, but human studies have been restricted by
cannabis’ Schedule I drug listing under federal law
and the stigma cannabis continues to have among the
general population. This has severely limited the
availability of research-grown cannabis. Since the
1960s, the federal government has only approved the
University of Mississippi’s School of Pharmacy to
grow cannabis. In 2013, the University had about 34
pounds of medical cannabis available for researchers.
www.npjournal.org

Currently, there are over 12 acres and an indoor
nursery, which together provide about 1,400 pounds
of cannabis grown solely for medical research and
scientiﬁc studies.26 With the signiﬁcant increase in
cannabis research, the Drug Enforcement
Administration was again petitioned to change
cannabis from a Schedule I to a Schedule II drug
classiﬁcation. This petition was denied on July 19,
2016, citing cannabis has “no currently accepted
medical use” in patient treatment. It was cited that
the drug chemistries are not standardized and
reproducible and there is lack of scientiﬁc evidence
and safety studies proving drug efﬁcacy. There was
also concern about the potential for abuse of
the drugs.34
The botanists at the University of Mississippi work
closely with pharmaceutical companies and researchers to provide crops to meet their unique and
speciﬁc needs for the illness they are targeting. The
scientists genetically modify the cannabis plant concentrations of THC and CBD.26 Once the
cannabinoid strains are chosen and procured for
medical use, drug companies must then decide on the
mechanism of delivery and which biochemical form
they would like to use.
HEALTH-CARE PROVIDER CONCERNS

If the fast-paced research continues in its present direction, then providers will need to decide how they
wish to proceed if asked to prescribe cannabis-based
drugs. There are continued numerous concerns
regarding cannabis use if laws and regulations remain
the same. On a daily basis, providers face certain
challenges should they choose to prescribe cannabis
for their patients. For example, as long as federal law
deﬁnes cannabis as a Schedule I drug, then states with
legalized cannabis are in direct conﬂict with federal
law. Today, medical cannabis is legal in 25 states and
the District of Columbia. Despite having state law
approval, providers could be subject to prosecution
according to federal laws. However, most federal law
enforcement agencies have left the policing of instate marijuana cases to state authorities, resulting in
national prosecutors refraining from pursuing states
and their medical providers who are currently prescribing medical cannabis.35 Yet, this does not
alleviate the risk a provider takes when prescribing
The Journal for Nurse Practitioners - JNP
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medical cannabis because the federal government
could decide to take a new position on enforcement
at any time.36
Nurse practitioners must also be concerned with
state-speciﬁc regulations. In states where medical
cannabis use has been legalized, there continues to be
no medical practice standardization across state lines.
Each state determines the medical conditions that
may or may not be treated. Often these conditions
include a handful of serious illnesses, which have
failed to respond to conventional treatment modalities. This makes it difﬁcult to provide continuity of
care to patients who have moved from one state to
another. The provider must also be aware and
compliant with the state-mandated medical documentation requirements, which include the frequency of re-evaluation for the medical condition
being treated. Many states also differ in who can
prescribe cannabis. Some states may only allow
certain specialists, such as neurologists and oncologists, to prescribe cannabis medications. Qualiﬁed
providers then write a recommendation stating the
patient would beneﬁt from medical cannabis.36
However, without FDA guidelines and the
standardization of medical cannabis drugs, patients
and providers are left to determine proper dosing
regimens on their own.
Once patients receive their medication, struggles
may persist as far as who can administer it and when it
can be taken. The continued conﬂict between state
and federal laws may put nurses and parents who
administer medical cannabis at risk for legal prosecution. For example, Colorado is currently reviewing
its laws on allowing students with valid prescriptions
to use edible medicinal cannabis in public schools.
The Colorado law states it is permissible for the
school nurse or parent to administer the medicinal
cannabis as long as the school district agrees.
Currently, no school district has given its approval. In
addition, school nurses are in conﬂict because they
are required by federal law to report to authorities
any child exposed to illegal drugs, which includes
cannabis-derived preparations.37
These regulatory inconsistencies between state
and federal law leave many nurse practitioners
reluctant to offer cannabis-based medicines, even
when it is justiﬁed and may the best available option
530
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for the patient. Providers also fear it puts the patient
at risk because human research cannabis trials are
limited and there is no standardization of medical
cannabis drug regimens.
CONCLUSIONS

As a basic review, it is important for nurse practitioners to understand the functioning of the ECS and
its potential to treat many disease processes. Up to
now, medical cannabis research, with human subjects, has been limited by federal law and the availability of government-sanctioned research on
cannabis. As the interest in cannabis medical research
accelerates, and involvement of pharmaceutical
companies in developing cannabis-based treatments
grows, research needs to be expanded to include
human subjects. This comes at a time in American
culture when there is a strong movement to discuss
and legalize cannabis for both medical and recreational use. Currently, 4 states have legalized cannabis
for recreational use and 25 states have laws sanctioning medical applications.38
There continues to be both state and national
debate regarding changing cannabis from a Schedule
I to Schedule II drug. Although states continue to
legalize medical cannabis, there is inconsistency in
law and policies and direct conﬂict with federal laws.
It is hoped that a resolution will occur in which the
federal government will allow and encourage
continued quality cannabis medical research to be
done to determine the actual efﬁcacy and safety of
cannabis in treating human disease processes.
It is important for nurse practitioners who
recommend cannabis-based drugs to keep current on
the latest legal prescriptive information as the conﬂict
between federal and state laws continues. It is hoped
that, as the conﬂict resolves and quality cannabis
research is carried out, the ECS and cannabis-based
drugs will offer new treatment options for patients
with serious diseases refractory to conventional
treatments.
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